Cargando…

Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review

OBJECTIVE: The role of neoadjuvant therapy (NAT) in resectable pancreatic cancer (RPC) remains controversial. Therefore, this meta-analysis was performed to compare the clinical differences between NAT and upfront surgery in RPC. MATERIALS AND METHODS: A systematic literature search was performed in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Xiaohan, Wei, Xiyi, Ding, Yichao, Qi, Feng, Zhang, Yundi, Hu, Xin, Qin, Chao, Li, Xiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348975/ https://www.ncbi.nlm.nih.gov/pubmed/30774360 http://dx.doi.org/10.2147/OTT.S190810

Ejemplares similares

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study
por: Su, Yung-Yeh, et al.
Publicado: (2023)

Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
por: Jeon, Hyun Jeong, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
por: Ghanem, I., et al.
Publicado: (2022)

Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Jung, Hye-Sol, et al.
Publicado: (2022)

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis
por: Liu, Zhen, et al.
Publicado: (2022)

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2022)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Ratnayake, Bathiya, et al.
Publicado: (2020)

A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study’
por: Chen, Yuan, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer
por: Zwart, Eline S., et al.
Publicado: (2023)

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2019)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis
por: Chen, Xing, et al.
Publicado: (2017)

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Zou, Yiping, et al.
Publicado: (2023)

Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
por: Yang, Zijiao, et al.
Publicado: (2023)

Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment
por: Fujii, Tsutomu, et al.
Publicado: (2015)

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications
por: Deig, Christopher Ryan, et al.
Publicado: (2022)

Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review
por: Fiflis, Stylianos, et al.
Publicado: (2023)

Neoadjuvant therapy or upfront surgery in advanced endometrial cancer: a systematic review protocol
por: McCarthy, Amy, et al.
Publicado: (2021)

Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma
por: Nappo, Gennaro, et al.
Publicado: (2023)

An invited commentary on ‘Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study’
por: Coppola, Alessandro, et al.
Publicado: (2023)

Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies
por: Pecorelli, Nicolò, et al.
Publicado: (2022)

Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients
por: Han, Myung Hyun, et al.
Publicado: (2019)

Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials
por: Zhang, Xiao-Nan, et al.
Publicado: (2017)

Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer
por: Miksch, Rainer C., et al.
Publicado: (2019)

Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma
por: Brugel, M., et al.
Publicado: (2021)

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
por: Zhu, Lingyu, et al.
Publicado: (2023)

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
por: Shrestha, Bikram, et al.
Publicado: (2017)

Upfront surgery in patients with epithelial ovarian cancer and enlarged supradiaphragmatic lymph nodes associated with comparable to neoadjuvant chemotherapy
por: Weitzner, Omer, et al.
Publicado: (2022)

Neoadjuvant therapy for resectable pancreatic cancer
por: Rahman, Sheikh Hasibur, et al.
Publicado: (2017)

Neoadjuvant therapy for resectable pancreatic cancers
por: Inoue, Yosuke, et al.
Publicado: (2022)

Survival Advantage of Upfront Surgery for Pancreatic Head Cancer Without Preoperative Biliary Drainage
por: Pande, Rupaly, et al.
Publicado: (2020)

Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
por: Lee, Seung Jae, et al.
Publicado: (2022)

Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach
por: Palumbo, Diego, et al.
Publicado: (2021)

Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis
por: Maloney, Sarah, et al.
Publicado: (2021)

Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis
por: Wu, Liucheng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cl740kkg545ml7oh5b2f000een